<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35464304</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1792-1082</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Oncology letters</Title>
          <ISOAbbreviation>Oncol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>3D cell culture alters signal transduction and drug response in head and neck squamous cell carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>177</StartPage>
          <MedlinePgn>177</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">177</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/ol.2022.13297</ELocationID>
        <Abstract>
          <AbstractText>Epidermal growth factor receptor (EGFR) upregulation is a typical characteristic of head and neck squamous cell carcinoma (HNSCC). However, tyrosine kinase inhibitors have not yet been able to achieve enough therapeutic benefit in clinical trials to justify their use in standard therapy regimens. At present, little is known about the reasons for this treatment failure. In the present study, the HNSCC cell lines UM-SCC-11B and UM-SCC-22B were tested for their response to tyrosine kinase inhibitors (TKI) under 2D and 3D cell culture conditions. Absorption and luciferase-based viability assays were used for this, as well as optical evaluation via fluorescence microscopy. In addition, EGFR and HER3 expression as well as the downstream signalling pathways PI3K/AKT/mTOR and RAS/RAF/MEK/ERK were investigated using western blotting. Cell line UM-SCC-11B revealed a strong resistance to lapatinib under 3D cell culture conditions, while a good response to TKI therapy was observed under 2D cell culture conditions. An associated overexpression of phosphorylated HER3 under 3D cell culture conditions offered a plausible explanation for the altered treatment response. The results of the present study represent an idea of how signalling mechanisms of cancer cells can be changed using different cell culture methods. Overall, 3D cell culture could be an important component in the analysis of resistance mechanisms in cancer therapy.</AbstractText>
          <CopyrightInformation>Copyright: © Heid et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Heid</LastName>
            <ForeName>Jonas</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Affolter</LastName>
            <ForeName>Annette</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jakob</LastName>
            <ForeName>Yvonne</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kern</LastName>
            <ForeName>Johann</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rotter</LastName>
            <ForeName>Nicole</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tenschert</LastName>
            <ForeName>Esther</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lammert</LastName>
            <ForeName>Anne</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Oncol Lett</MedlineTA>
        <NlmUniqueID>101531236</NlmUniqueID>
        <ISSNLinking>1792-1074</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">HER3 expression</Keyword>
        <Keyword MajorTopicYN="N">afatinib</Keyword>
        <Keyword MajorTopicYN="N">epidermal growth factor receptor</Keyword>
        <Keyword MajorTopicYN="N">lapatinib</Keyword>
        <Keyword MajorTopicYN="N">spheroid culture</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35464304</ArticleId>
        <ArticleId IdType="pmc">PMC9021830</ArticleId>
        <ArticleId IdType="doi">10.3892/ol.2022.13297</ArticleId>
        <ArticleId IdType="pii">OL-23-06-13297</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29210</ArticleId>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol. 2004;31:726–733. doi: 10.1053/j.seminoncol.2004.09.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.seminoncol.2004.09.013</ArticleId>
            <ArticleId IdType="pubmed">15599850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF., Jr Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;48:3282–3287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3365707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579–3584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8339264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res. 2006;12:5268–5272. doi: 10.1158/1078-0432.CCR-05-1554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-05-1554</ArticleId>
            <ArticleId IdType="pubmed">17000658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4055302</ArticleId>
            <ArticleId IdType="pubmed">24963404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey RD, Adams VR, Beardslee T, Medina P. Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. J Oncol Pharm Pract. 2020;26:1461–1474. doi: 10.1177/1078155220931926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1078155220931926</ArticleId>
            <ArticleId IdType="pmc">PMC7448811</ArticleId>
            <ArticleId IdType="pubmed">32567494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu ZQ, Zhang Y, Li N, Liu PJ, Gao L, Gao X, Tie XJ. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: A systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7:e013053. doi: 10.1136/bmjopen-2016-013053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2016-013053</ArticleId>
            <ArticleId IdType="pmc">PMC5353336</ArticleId>
            <ArticleId IdType="pubmed">28289045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171–2177. doi: 10.1200/JCO.2006.06.7447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2006.06.7447</ArticleId>
            <ArticleId IdType="pubmed">17538161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrarotto R, Gold KA. Afatinib in the treatment of head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2014;23:135–143. doi: 10.1517/13543784.2014.858696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543784.2014.858696</ArticleId>
            <ArticleId IdType="pubmed">24266694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC) Cancer Treat Rev. 2014;40:567–577. doi: 10.1016/j.ctrv.2013.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2013.10.002</ArticleId>
            <ArticleId IdType="pubmed">24216225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozakiewicz P, Grzybowska-Szatkowska L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. Oncol Lett. 2018;15:7497–7505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5920345</ArticleId>
            <ArticleId IdType="pubmed">29725456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss JM, Bagley S, Hwang WT, Bauml J, Olson JG, Cohen RB, Hayes DN, Langer C. Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer. 2016;122:2350–2355. doi: 10.1002/cncr.30067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.30067</ArticleId>
            <ArticleId IdType="pubmed">27197056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal V, Subash A, Nayar RC, Rao V. Is EGFR really a therapeutic target in head and neck cancers? J Surg Oncol. 2019;119:685–686. doi: 10.1002/jso.25387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.25387</ArticleId>
            <ArticleId IdType="pubmed">30701564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen EE, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, et al.  Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017;28:2526–2532. doi: 10.1093/annonc/mdx344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx344</ArticleId>
            <ArticleId IdType="pmc">PMC5834024</ArticleId>
            <ArticleId IdType="pubmed">28961833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picon H, Guddati AK. Mechanisms of resistance in head and neck cancer. Am J Cancer Res. 2020;10:2742–2751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7539768</ArticleId>
            <ArticleId IdType="pubmed">33042614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shuford S, Lipinski L, Abad A, Smith AM, Rayner M, O'Donnell L, Stuart J, Mechtler LL, Fabiano AJ, Edenfield J, et al.  Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. Neurooncol Adv. 2021;3:vdab065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8207705</ArticleId>
            <ArticleId IdType="pubmed">34142085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa EC, Moreira AF, de Melo-Diogo D, Gaspar VM, Carvalho MP, Correia IJ. 3D tumor spheroids: An overview on the tools and techniques used for their analysis. Biotechnol Adv. 2016;34:1427–1441. doi: 10.1016/j.biotechadv.2016.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biotechadv.2016.11.002</ArticleId>
            <ArticleId IdType="pubmed">27845258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104:973–978. doi: 10.1073/pnas.0610117104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0610117104</ArticleId>
            <ArticleId IdType="pmc">PMC1783424</ArticleId>
            <ArticleId IdType="pubmed">17210912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, Wicha MS, Prince ME. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32:1195–1201. doi: 10.1002/hed.21315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hed.21315</ArticleId>
            <ArticleId IdType="pmc">PMC2991066</ArticleId>
            <ArticleId IdType="pubmed">20073073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tahmasebi E, Alikhani M, Yazdanian A, Yazdanian M, Tebyanian H, Seifalian A. The current markers of cancer stem cell in oral cancers. Life Sci. 2020;249:117483. doi: 10.1016/j.lfs.2020.117483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2020.117483</ArticleId>
            <ArticleId IdType="pubmed">32135187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 2007;130:601–610. doi: 10.1016/j.cell.2007.08.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.08.006</ArticleId>
            <ArticleId IdType="pubmed">17719539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayuso JM, Vitek R, Swick AD, Skala MC, Wisinski KB, Kimple RJ, Lambert PF, Beebe DJ. Effects of culture method on response to EGFR therapy in head and neck squamous cell carcinoma cells. Sci Rep. 2019;9:12480. doi: 10.1038/s41598-019-48764-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-48764-3</ArticleId>
            <ArticleId IdType="pmc">PMC6713778</ArticleId>
            <ArticleId IdType="pubmed">31462653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan YH, Lee YC, Hung CY, Yang PJ, Lai PC, Feng SW. Three-dimensional spheroid culture enhances multipotent differentiation and stemness capacities of human dental pulp-derived mesenchymal stem cells by modulating MAPK and NF-kB signaling pathways. Stem Cell Rev Rep. 2021;17:1810–1826. doi: 10.1007/s12015-021-10172-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12015-021-10172-4</ArticleId>
            <ArticleId IdType="pubmed">33893620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HK, Noh MH, Hong SW, Kim SM, Kim SH, Kim YS, Broaddus VC, Hur DY. Erlotinib activates different cell death pathways in EGFR-mutant lung cancer cells grown in 3D versus 2D culture systems. Anticancer Res. 2021;41:1261–1269. doi: 10.21873/anticanres.14883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21873/anticanres.14883</ArticleId>
            <ArticleId IdType="pubmed">33788717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DelNero P, Lane M, Verbridge SS, Kwee B, Kermani P, Hempstead B, Stroock A, Fischbach C. 3D culture broadly regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways. Biomaterials. 2015;55:110–118. doi: 10.1016/j.biomaterials.2015.03.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2015.03.035</ArticleId>
            <ArticleId IdType="pmc">PMC4417672</ArticleId>
            <ArticleId IdType="pubmed">25934456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontoura JC, Viezzer C, Dos Santos FG, Ligabue RA, Weinlich R, Puga RD, Antonow D, Severino P, Bonorino C. Comparison of 2D and 3D cell culture models for cell growth, gene expression and drug resistance. Mater Sci Eng C Mater Biol Appl. 2020;107:110264. doi: 10.1016/j.msec.2019.110264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msec.2019.110264</ArticleId>
            <ArticleId IdType="pubmed">31761183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt M, Scholz CJ, Polednik C, Roller J. Spheroid-based 3-dimensional culture models: Gene expression and functionality in head and neck cancer. Oncol Rep. 2016;35:2431–2440. doi: 10.3892/or.2016.4581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2016.4581</ArticleId>
            <ArticleId IdType="pubmed">26797047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S, Nakatsura T, Minami H. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep. 2015;33:1837–1843. doi: 10.3892/or.2015.3767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2015.3767</ArticleId>
            <ArticleId IdType="pubmed">25634491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosaad E, Chambers K, Futrega K, Clements J, Doran MR. Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures. BMC Cancer. 2018;18:592. doi: 10.1186/s12885-018-4473-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-018-4473-8</ArticleId>
            <ArticleId IdType="pmc">PMC5968610</ArticleId>
            <ArticleId IdType="pubmed">29793440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. Cancer Med. 2019;8:1258–1268. doi: 10.1002/cam4.1995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.1995</ArticleId>
            <ArticleId IdType="pmc">PMC6434202</ArticleId>
            <ArticleId IdType="pubmed">30701699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Temraz S, Mukherji D, Shamseddine A. Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. Crit Rev Oncol Hematol. 2016;101:151–157. doi: 10.1016/j.critrevonc.2016.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.critrevonc.2016.03.009</ArticleId>
            <ArticleId IdType="pubmed">27017409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D, Qian G, Zhang H, Magliocca KR, Nannapaneni S, Amin AR, Rossi M, Patel M, El-Deiry M, Wadsworth JT, et al.  HER3 targeting sensitizes HNSCC to cetuximab by reducing HER3 activity and HER2/HER3 dimerization: Evidence from cell line and patient-derived xenograft models. Clin Cancer Res. 2017;23:677–686. doi: 10.1158/1078-0432.CCR-16-0558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-0558</ArticleId>
            <ArticleId IdType="pmc">PMC5199640</ArticleId>
            <ArticleId IdType="pubmed">27358485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, et al.  Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab. Mol Cancer Ther. 2016;15:2175–2186. doi: 10.1158/1535-7163.MCT-16-0012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-16-0012</ArticleId>
            <ArticleId IdType="pmc">PMC5010956</ArticleId>
            <ArticleId IdType="pubmed">27422810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von der Grün J, Rödel F, Brandts C, Fokas E, Guckenberger M, Rödel C, Balermpas P. Targeted therapies and immune-checkpoint inhibition in head and neck squamous cell carcinoma: Where do we stand today and where to go? Cancers (Basel) 2019;11:472. doi: 10.3390/cancers11040472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11040472</ArticleId>
            <ArticleId IdType="pmc">PMC6521064</ArticleId>
            <ArticleId IdType="pubmed">30987257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH, Kim SB, Bello M, Arora RS, Zhang Q, He X, et al.  Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-head &amp; neck 3): an open-label, randomised phase III trial. Ann Oncol. 2019;30:1831–1839. doi: 10.1093/annonc/mdz388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz388</ArticleId>
            <ArticleId IdType="pmc">PMC6927323</ArticleId>
            <ArticleId IdType="pubmed">31501887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20:398–411. doi: 10.1038/s41568-020-0263-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-020-0263-0</ArticleId>
            <ArticleId IdType="pubmed">32488200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faber A, Aderhold C, Goessler UR, Hoermann K, Schultz JD, Umbreit C, Walliczek U, Stern-Straeter J. Interaction of a CD44+ head and neck squamous cell carcinoma cell line with a stromal cell-derived factor-1-expressing supportive niche: An in vitro model. Oncol Lett. 2014;7:82–86. doi: 10.3892/ol.2013.1673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2013.1673</ArticleId>
            <ArticleId IdType="pmc">PMC3861560</ArticleId>
            <ArticleId IdType="pubmed">24348826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lammert A, Affolter A, Gvaramia D, Heid J, Jungbauer F, Scherl C, Tenschert E, Rotter N, Willett N, Kern J. The tumor stem cell niche of head and neck-point of intersection with therapeutic potential? Laryngorhinootologie. 2021;100:23–29. (In German)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33401320</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35464304</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1792-1082</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Oncology letters</Title>
          <ISOAbbreviation>Oncol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>3D cell culture alters signal transduction and drug response in head and neck squamous cell carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>177</StartPage>
          <MedlinePgn>177</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">177</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/ol.2022.13297</ELocationID>
        <Abstract>
          <AbstractText>Epidermal growth factor receptor (EGFR) upregulation is a typical characteristic of head and neck squamous cell carcinoma (HNSCC). However, tyrosine kinase inhibitors have not yet been able to achieve enough therapeutic benefit in clinical trials to justify their use in standard therapy regimens. At present, little is known about the reasons for this treatment failure. In the present study, the HNSCC cell lines UM-SCC-11B and UM-SCC-22B were tested for their response to tyrosine kinase inhibitors (TKI) under 2D and 3D cell culture conditions. Absorption and luciferase-based viability assays were used for this, as well as optical evaluation via fluorescence microscopy. In addition, EGFR and HER3 expression as well as the downstream signalling pathways PI3K/AKT/mTOR and RAS/RAF/MEK/ERK were investigated using western blotting. Cell line UM-SCC-11B revealed a strong resistance to lapatinib under 3D cell culture conditions, while a good response to TKI therapy was observed under 2D cell culture conditions. An associated overexpression of phosphorylated HER3 under 3D cell culture conditions offered a plausible explanation for the altered treatment response. The results of the present study represent an idea of how signalling mechanisms of cancer cells can be changed using different cell culture methods. Overall, 3D cell culture could be an important component in the analysis of resistance mechanisms in cancer therapy.</AbstractText>
          <CopyrightInformation>Copyright: © Heid et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Heid</LastName>
            <ForeName>Jonas</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Affolter</LastName>
            <ForeName>Annette</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jakob</LastName>
            <ForeName>Yvonne</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kern</LastName>
            <ForeName>Johann</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rotter</LastName>
            <ForeName>Nicole</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tenschert</LastName>
            <ForeName>Esther</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lammert</LastName>
            <ForeName>Anne</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, D-68167 Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Oncol Lett</MedlineTA>
        <NlmUniqueID>101531236</NlmUniqueID>
        <ISSNLinking>1792-1074</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">HER3 expression</Keyword>
        <Keyword MajorTopicYN="N">afatinib</Keyword>
        <Keyword MajorTopicYN="N">epidermal growth factor receptor</Keyword>
        <Keyword MajorTopicYN="N">lapatinib</Keyword>
        <Keyword MajorTopicYN="N">spheroid culture</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35464304</ArticleId>
        <ArticleId IdType="pmc">PMC9021830</ArticleId>
        <ArticleId IdType="doi">10.3892/ol.2022.13297</ArticleId>
        <ArticleId IdType="pii">OL-23-06-13297</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29210</ArticleId>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol. 2004;31:726–733. doi: 10.1053/j.seminoncol.2004.09.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.seminoncol.2004.09.013</ArticleId>
            <ArticleId IdType="pubmed">15599850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF., Jr Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;48:3282–3287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3365707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579–3584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8339264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res. 2006;12:5268–5272. doi: 10.1158/1078-0432.CCR-05-1554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-05-1554</ArticleId>
            <ArticleId IdType="pubmed">17000658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4055302</ArticleId>
            <ArticleId IdType="pubmed">24963404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey RD, Adams VR, Beardslee T, Medina P. Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. J Oncol Pharm Pract. 2020;26:1461–1474. doi: 10.1177/1078155220931926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1078155220931926</ArticleId>
            <ArticleId IdType="pmc">PMC7448811</ArticleId>
            <ArticleId IdType="pubmed">32567494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu ZQ, Zhang Y, Li N, Liu PJ, Gao L, Gao X, Tie XJ. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: A systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7:e013053. doi: 10.1136/bmjopen-2016-013053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2016-013053</ArticleId>
            <ArticleId IdType="pmc">PMC5353336</ArticleId>
            <ArticleId IdType="pubmed">28289045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171–2177. doi: 10.1200/JCO.2006.06.7447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2006.06.7447</ArticleId>
            <ArticleId IdType="pubmed">17538161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrarotto R, Gold KA. Afatinib in the treatment of head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2014;23:135–143. doi: 10.1517/13543784.2014.858696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543784.2014.858696</ArticleId>
            <ArticleId IdType="pubmed">24266694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC) Cancer Treat Rev. 2014;40:567–577. doi: 10.1016/j.ctrv.2013.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2013.10.002</ArticleId>
            <ArticleId IdType="pubmed">24216225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozakiewicz P, Grzybowska-Szatkowska L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. Oncol Lett. 2018;15:7497–7505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5920345</ArticleId>
            <ArticleId IdType="pubmed">29725456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss JM, Bagley S, Hwang WT, Bauml J, Olson JG, Cohen RB, Hayes DN, Langer C. Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer. 2016;122:2350–2355. doi: 10.1002/cncr.30067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.30067</ArticleId>
            <ArticleId IdType="pubmed">27197056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal V, Subash A, Nayar RC, Rao V. Is EGFR really a therapeutic target in head and neck cancers? J Surg Oncol. 2019;119:685–686. doi: 10.1002/jso.25387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.25387</ArticleId>
            <ArticleId IdType="pubmed">30701564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen EE, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, et al.  Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017;28:2526–2532. doi: 10.1093/annonc/mdx344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx344</ArticleId>
            <ArticleId IdType="pmc">PMC5834024</ArticleId>
            <ArticleId IdType="pubmed">28961833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picon H, Guddati AK. Mechanisms of resistance in head and neck cancer. Am J Cancer Res. 2020;10:2742–2751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7539768</ArticleId>
            <ArticleId IdType="pubmed">33042614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shuford S, Lipinski L, Abad A, Smith AM, Rayner M, O'Donnell L, Stuart J, Mechtler LL, Fabiano AJ, Edenfield J, et al.  Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. Neurooncol Adv. 2021;3:vdab065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8207705</ArticleId>
            <ArticleId IdType="pubmed">34142085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa EC, Moreira AF, de Melo-Diogo D, Gaspar VM, Carvalho MP, Correia IJ. 3D tumor spheroids: An overview on the tools and techniques used for their analysis. Biotechnol Adv. 2016;34:1427–1441. doi: 10.1016/j.biotechadv.2016.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biotechadv.2016.11.002</ArticleId>
            <ArticleId IdType="pubmed">27845258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104:973–978. doi: 10.1073/pnas.0610117104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0610117104</ArticleId>
            <ArticleId IdType="pmc">PMC1783424</ArticleId>
            <ArticleId IdType="pubmed">17210912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, Wicha MS, Prince ME. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32:1195–1201. doi: 10.1002/hed.21315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hed.21315</ArticleId>
            <ArticleId IdType="pmc">PMC2991066</ArticleId>
            <ArticleId IdType="pubmed">20073073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tahmasebi E, Alikhani M, Yazdanian A, Yazdanian M, Tebyanian H, Seifalian A. The current markers of cancer stem cell in oral cancers. Life Sci. 2020;249:117483. doi: 10.1016/j.lfs.2020.117483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2020.117483</ArticleId>
            <ArticleId IdType="pubmed">32135187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 2007;130:601–610. doi: 10.1016/j.cell.2007.08.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.08.006</ArticleId>
            <ArticleId IdType="pubmed">17719539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayuso JM, Vitek R, Swick AD, Skala MC, Wisinski KB, Kimple RJ, Lambert PF, Beebe DJ. Effects of culture method on response to EGFR therapy in head and neck squamous cell carcinoma cells. Sci Rep. 2019;9:12480. doi: 10.1038/s41598-019-48764-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-48764-3</ArticleId>
            <ArticleId IdType="pmc">PMC6713778</ArticleId>
            <ArticleId IdType="pubmed">31462653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan YH, Lee YC, Hung CY, Yang PJ, Lai PC, Feng SW. Three-dimensional spheroid culture enhances multipotent differentiation and stemness capacities of human dental pulp-derived mesenchymal stem cells by modulating MAPK and NF-kB signaling pathways. Stem Cell Rev Rep. 2021;17:1810–1826. doi: 10.1007/s12015-021-10172-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12015-021-10172-4</ArticleId>
            <ArticleId IdType="pubmed">33893620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HK, Noh MH, Hong SW, Kim SM, Kim SH, Kim YS, Broaddus VC, Hur DY. Erlotinib activates different cell death pathways in EGFR-mutant lung cancer cells grown in 3D versus 2D culture systems. Anticancer Res. 2021;41:1261–1269. doi: 10.21873/anticanres.14883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21873/anticanres.14883</ArticleId>
            <ArticleId IdType="pubmed">33788717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DelNero P, Lane M, Verbridge SS, Kwee B, Kermani P, Hempstead B, Stroock A, Fischbach C. 3D culture broadly regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways. Biomaterials. 2015;55:110–118. doi: 10.1016/j.biomaterials.2015.03.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2015.03.035</ArticleId>
            <ArticleId IdType="pmc">PMC4417672</ArticleId>
            <ArticleId IdType="pubmed">25934456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontoura JC, Viezzer C, Dos Santos FG, Ligabue RA, Weinlich R, Puga RD, Antonow D, Severino P, Bonorino C. Comparison of 2D and 3D cell culture models for cell growth, gene expression and drug resistance. Mater Sci Eng C Mater Biol Appl. 2020;107:110264. doi: 10.1016/j.msec.2019.110264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msec.2019.110264</ArticleId>
            <ArticleId IdType="pubmed">31761183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt M, Scholz CJ, Polednik C, Roller J. Spheroid-based 3-dimensional culture models: Gene expression and functionality in head and neck cancer. Oncol Rep. 2016;35:2431–2440. doi: 10.3892/or.2016.4581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2016.4581</ArticleId>
            <ArticleId IdType="pubmed">26797047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S, Nakatsura T, Minami H. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep. 2015;33:1837–1843. doi: 10.3892/or.2015.3767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2015.3767</ArticleId>
            <ArticleId IdType="pubmed">25634491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosaad E, Chambers K, Futrega K, Clements J, Doran MR. Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures. BMC Cancer. 2018;18:592. doi: 10.1186/s12885-018-4473-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-018-4473-8</ArticleId>
            <ArticleId IdType="pmc">PMC5968610</ArticleId>
            <ArticleId IdType="pubmed">29793440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. Cancer Med. 2019;8:1258–1268. doi: 10.1002/cam4.1995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.1995</ArticleId>
            <ArticleId IdType="pmc">PMC6434202</ArticleId>
            <ArticleId IdType="pubmed">30701699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Temraz S, Mukherji D, Shamseddine A. Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. Crit Rev Oncol Hematol. 2016;101:151–157. doi: 10.1016/j.critrevonc.2016.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.critrevonc.2016.03.009</ArticleId>
            <ArticleId IdType="pubmed">27017409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D, Qian G, Zhang H, Magliocca KR, Nannapaneni S, Amin AR, Rossi M, Patel M, El-Deiry M, Wadsworth JT, et al.  HER3 targeting sensitizes HNSCC to cetuximab by reducing HER3 activity and HER2/HER3 dimerization: Evidence from cell line and patient-derived xenograft models. Clin Cancer Res. 2017;23:677–686. doi: 10.1158/1078-0432.CCR-16-0558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-0558</ArticleId>
            <ArticleId IdType="pmc">PMC5199640</ArticleId>
            <ArticleId IdType="pubmed">27358485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, et al.  Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab. Mol Cancer Ther. 2016;15:2175–2186. doi: 10.1158/1535-7163.MCT-16-0012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-16-0012</ArticleId>
            <ArticleId IdType="pmc">PMC5010956</ArticleId>
            <ArticleId IdType="pubmed">27422810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von der Grün J, Rödel F, Brandts C, Fokas E, Guckenberger M, Rödel C, Balermpas P. Targeted therapies and immune-checkpoint inhibition in head and neck squamous cell carcinoma: Where do we stand today and where to go? Cancers (Basel) 2019;11:472. doi: 10.3390/cancers11040472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11040472</ArticleId>
            <ArticleId IdType="pmc">PMC6521064</ArticleId>
            <ArticleId IdType="pubmed">30987257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH, Kim SB, Bello M, Arora RS, Zhang Q, He X, et al.  Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-head &amp; neck 3): an open-label, randomised phase III trial. Ann Oncol. 2019;30:1831–1839. doi: 10.1093/annonc/mdz388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz388</ArticleId>
            <ArticleId IdType="pmc">PMC6927323</ArticleId>
            <ArticleId IdType="pubmed">31501887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20:398–411. doi: 10.1038/s41568-020-0263-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-020-0263-0</ArticleId>
            <ArticleId IdType="pubmed">32488200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faber A, Aderhold C, Goessler UR, Hoermann K, Schultz JD, Umbreit C, Walliczek U, Stern-Straeter J. Interaction of a CD44+ head and neck squamous cell carcinoma cell line with a stromal cell-derived factor-1-expressing supportive niche: An in vitro model. Oncol Lett. 2014;7:82–86. doi: 10.3892/ol.2013.1673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2013.1673</ArticleId>
            <ArticleId IdType="pmc">PMC3861560</ArticleId>
            <ArticleId IdType="pubmed">24348826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lammert A, Affolter A, Gvaramia D, Heid J, Jungbauer F, Scherl C, Tenschert E, Rotter N, Willett N, Kern J. The tumor stem cell niche of head and neck-point of intersection with therapeutic potential? Laryngorhinootologie. 2021;100:23–29. (In German)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33401320</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
